On Aug 18, 2021 Immunitas Therapeutics closed a Series B round and raised $58,000,000 from 120 Capital Management, Agent Capital, Alexandria Venture Investments, BrightEdge Fund, Evotec, Leaps by Bayer, Leukemia & Lymphoma Society, Longwood Fund, M Ventures, Medical Excellence Capital, Mirae Asset Global Investments, Novartis Venture Fund, NS Investment, Ono Venture Investment, Solasta Ventures, The Mark Foundation for Cancer Research, featuring lead investors Agent Capital.

About the company: Immunitas Therapeutics is located at United States, North America.
“”

Company website: www.immunitastx.com/